Latest Breaking News On - Hidradenitis suppurativa - Page 1 : comparemela.com

Bimekizumab safe and effective for treatment of moderate-to-severe hidradenitis suppurative

1. Significantly more patients in the bimekizumab group than placebo reported improved clinical response at week 16. 2. Treatment-related adverse events were infrequent with one fatality across both treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Hidradenitis suppurativa (HiS) is a chronic inflammatory disease with limited therapeutic options. Bimekizumab, a monoclonal IgG1 antibody that

HS advocate Jasmine 'Ivanna' Espy's AHSID Organization Hosts Its First In-Person Summit

Acelyrin, Inc. Expected to Post Q2 2024 Earnings of ($0.33) Per Share (NASDAQ:SLRN)

Acelyrin, Inc. (NASDAQ:SLRN – Free Report) – Equities researchers at HC Wainwright boosted their Q2 2024 EPS estimates for shares of Acelyrin in a report released on Wednesday, May 22nd. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($0.33) for the quarter, up from their previous estimate […]

UCB : announces publication in The Lancet of phase 3 bimekizumab▼ trials in moderate to severe hidradenitis suppurativa

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa